REGENXBIO Hits FDA Clinical Hold on RGX-111 and RGX-121 Trials After Tumor Discovery
FDA placed clinical holds on REGENXBIO’s RGX-111 and RGX-121 gene therapy trials after a routine MRI detected an intraventricular CNS tumor in a five-year-old Phase I/II RGX-111 participant. Preliminary analysis showed AAV vector integration near the PLAG1 proto-oncogene, and causality is still under investigation.
1. FDA Imposes Clinical Holds on RGX-111 and RGX-121 Programs
On January 28, 2026, the U.S. Food and Drug Administration placed a full clinical hold on REGENXBIO’s investigational gene therapies RGX-111 for MPS I (Hurler syndrome) and RGX-121 for MPS II (Hunter syndrome). The action follows a routine safety review that identified a single case of an intraventricular central nervous system tumor in a five-year-old participant dosed with RGX-111 four years earlier. The FDA cited similarities in vector design, patient population, and potential shared risk across both programs, halting dosing and new enrollments until REGENXBIO provides further data and analysis.
2. Tumor Case Details and Ongoing Investigation
The neoplasm was discovered during a scheduled brain MRI in an asymptomatic participant. Surgical resection and genetic analysis revealed integration of the AAV vector genome near the PLAG1 proto-oncogene, driving overexpression associated with chromosomal rearrangements. REGENXBIO reports no other tumors in the nine additional RGX-111 patients or the 32 patients treated with RGX-121. The company is conducting a root-cause investigation to determine causality and has not yet received the official clinical hold letter, delaying its response timeline.
3. Company Response and Safety Profile Emphasis
REGENXBIO’s President and CEO Curran Simpson emphasized confidence in RGX-121’s established safety record, noting over seven years of follow-up data in a pediatric population with no serious adverse events of this nature. The company underscored its commitment to patient safety, highlighting positive neurodevelopmental outcomes in the RGX-121 pivotal trial and multiple FDA designations—Orphan Drug, Rare Pediatric Disease, Fast Track and RMAT—that underline the therapy’s potential to address severe unmet medical needs in MPS II.
4. Investor Implications and Next Steps
The holds introduce regulatory uncertainty ahead of key 2026 catalysts, including the February PDUFA decision for RGX-121 and interim data from the RGX-202 Duchenne muscular dystrophy program. REGENXBIO’s shares could face volatility as the market awaits the FDA’s full rationale and the company’s proposed mitigation strategies. Management expects to submit comprehensive safety analyses and epidemiological context to the agency in coming weeks, with potential lifting of the hold contingent on demonstration that the tumor event is isolated and not product-related.